NCT02929823 - Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

May 3, 2017

Study Completion Date

May 3, 2017

Conditions

Corneal Epithelial Disorders

Interventions

DRUG

High Dose SJP-0035 Ophthalmic Solution

0.001% SJP-0035 Ophthalmic Solution

DRUG

Low Dose SJP-0035 Ophthalmic Solution

0.0002% SJP-0035 Ophthalmic Solution

DRUG

Vehicle of SJP-0035 Ophthalmic solution

0% SJP-0035 Ophthalmic Solution

Trial Locations (19)

22044

Senju Investigational Site, Falls Church

23502

Senju Investigational Site, Norfolk

27262

Senju Investigational Site, High Point

33143

Senju Investigational Site, Miami

40206

Senju Investigational Site, Louisville

41017

Senju Investigational Site, Edgewood

57701

Senju Investigational Site, Rapid City

60169

Senju Investigational Site, Hoffman Estates

64111

Senju Investigational Site, Kansas City

72205

Senju Investigational Site, Little Rock

75039

Senju Investigational Site, Irving

77030

Senju Investigational Site, Houston

78613

Senju Investigational Site, Cedar Park

90640

Senju Investigational Site, Montebello

90805

Senju Investigational Site, Long Beach

91107

Senju Investigational Site, Pasadena

91741

Senju Investigational Site, Glendora

92705

Senju Investigational Site, Santa Ana

93534

Senju Investigational Site, Lancaster

All Listed Sponsors

lead

Senju Pharmaceutical Co., Ltd.

INDUSTRY